Preparation, characterization, pharmacokinetics, and bioactivity of honokiol-in-hydroxypropyl-β-cyclodextrin-in-liposome

Journal of Pharmaceutical Sciences

Volumn 100, Issue 8, 2011, Pages 3357-3364

  Wang, Xianhuo ^a,b   Deng, Linyu ^a   Cai, Lulu ^a   Zhang, Xiaoyan ^a   Zheng, Hao ^a   Deng, Chongyang ^a   Duan, Xingmei ^a   Zhao, Xia ^a   Wei, Yuquan ^a   Chen, Lijuan ^a  

^a SICHUAN UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Bioactivity; Crystallographic study; Cyclodextrins; Drug delivery systems; Honokiol; Hydroxypropyl cyclodextrin; Inclusion compounds; Liposomes; Pharmacokinetics

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; HONOKIOL; LIPOSOME;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG ACTIVITY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; PARTICLE SIZE; RAT; TUMOR CELL LINE; ZETA POTENTIAL;

EID: 79958818504     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22534     Document Type: Article

References (24)

1. Arima H, Yunomae K, Miyake K, Irie T, Hirayama F, Uekama K. 2001. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci 90:690-701.
2. Cappello B, Carmignani C, Iervolino M, Immacolata La Rotonda M, Fabrizio SM. 2001. Solubilization of tropicamide by hydroxypropyl-beta-cyclodextrin and water-soluble polymers: In vitro/in vivo studies. Int J Pharm 213:75-81.
3. Jarho P, Urtti A, Pate DW, Suhonen P, Jarvinen T. 1996. Increase in aqueous solubility, stability and in vitro corneal permeability of anandamide by hydroxypropyl-β-cyclodextrin. Int J Pharm 137:209-216.
4. Loftsson T, Jarvinen T. 1999. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev 36:59-79.
5. Irie T, Uekama K. 1997. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 86:147-162.
6. Gould S, Scott RC. 2005. 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review. Food Chem Toxicol 43:1451-1459.
7. McCormack B, Gregoriadis G. 1994. Drugs-in-cyclodextrins-in-liposomes: A novel concept in drug delivery. Int J Pharm 112:249-258.
8. McCormack B, Gregoriadis G. 1994. Entrapment of cyclodextrin-drug complexes into liposomes: Potential advantages in drug delivery. J Drug Target 2:449-454.
9. McCormack B, Gregoriadis G. 1998. Drugs-in-cyclodextrin-in-liposomes: An approach to controlling the fate of water insoluble drugs in vivo. Int J Pharm 162:59-69.
10. Loukas Y, Vraka V, Gregoriadis G. 1998. Drugs, in cyclodextrins, in liposomes: A novel approach to the chemical stability of drugs sensitive to hydrolysis. Int J Pharm 162:137-142.
11. Fatouros DG, Hatzidimitriou K, Antimisiaris SG. 2001. Liposomes encapsulating prednisolone and prednisolone-cyclodextrin complexes: Comparison of membrane integrity and drug release. Eur J Pharm Sci 13:287-296.
12. Syu WJ, Shen CC, Lu JJ, Lee GH, Sun CM. 2004. Antimicrobial and cytotoxic activities of neolignans from Magnolia officinalis. Chem Biodivers 1:530-538.
13. Pyo MK, Lee Y, Yun-Choi HS. 2002. Anti-platelet effect of the constituents isolated from the barks and fruits of Magnolia obovata. Arch Pharm Res 25:325-328.
14. Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK. 2003. The anti-inflammatory effect of honokiol on neutrophils: Mechanisms in the inhibition of reactive oxygen species production. Eur J Pharmacol 475:19-27.
15. Haraguchi H, Ishikawa H, Shirataki N, Fukuda A. 1997. Antiperoxidative activity of neolignans from Magnolia obovata. J Pharm Pharmacol 49:209-212.
16. Kuribara H, Kishi E, Kimura M, Weintraub ST, Maruyama Y. 2000. Comparative assessment of the anxiolytic-like activities of honokiol and derivatives. Pharmacol Biochem Behav 67(3):597-601.
17. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E, Dubiel W, Soff G, Arbiser JL. 2003. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 278:35501-35507.
18. Chen LJ, Zhang Q, Yang GL, Fan LY, Tang J, Garrard I, Ignatova S, Fisher D, Sutherland Ian A. 2007. Rapid purification and scale-up of honokiol and magnolol using high-capacity high-speed counter-current chromatography. J Chromatogr A 1142:115-122.
19. Yang SE, Hsieh MT, Tsai TH, Hsu SL. 2002. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochem Pharmacol 63:1641-1651.
20. Fong WF, Tse Anfernee KW, Poon KH, Wang C. 2005. Magnolol and honokiol enhance HL-60 human leukemia cell differentiation induced by 1.25-dihydroxyvitamin D3 and retinoic acid. Int J Biochem Cell Biol 37:427-441.
21. Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K, Eucker J. 2008. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Eur J Pharmacol 591:43-51.
22. Wei XW, Gong CY, Shi S, Fu SZ, Men K, Zeng S, Zheng XL, Gou ML, Chen LJ, Qiu LY, Qian ZY. 2009. Self-assembled honokiol-loaded micelles based on poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) copolymer. Int J Pharm 369:170-175.
23. Gou ML, Zheng L, Peng XY, Men K, Zheng XL, Zeng S, Gou G, Luo F, Zhao X, Chen LJ, Wei YQ, Qian ZY. 2009. Poly(ε-caprolactone)-poly (ethyleneglycol)-poly(ε-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro. Int J Pharm 375:170-176.
24. Liu L, Gou QX. 2002. The driving forces in the inclusion complexation of cyclodextrins. J Inclusion Phenom Macroc Chem 42:1-14.